The Spanish biopharmaceutical company expands its catalog of bioreagents with more than 100,000 new references thanks to the new international distribution agreement signed with Antibody Research Corp...
Read moreDeveloped by CNIO and the University of Vigo, the PanDrugs2 programme analyses alterations in tumour genes, relates them to existing available drugs, and reports on the most suitable ones
Read moreThe phase III randomized multi-center CAPItello-291 assessed the efficacy and safety of novel AKT inhibitor capivasertib plus fulvestrant in patients with advanced HR+/ HER2- breast cancer who had pro...
Read moreResearchers of the University of Barcelona and the Institute of Bioengineering of Catalonia (IBEC) have identified new biomarkers for non-small cell lung cancer, the most common l...
Read moreThe study, published in the journal Nature Communications, opens the door to the development of effective drug candidates that fully harness the therapeutic potential of Siglec-15. This knowledge will...
Read moreA study proposed an exhaustive study of the small RNA levels in the extracellular vesicles of the semen of azoospermic individuals. The objective was to select non-invasive biomarkers with diagnostic ...
Read moreEl sistema inmunitario se encarga de mantener los microbios patógenos a raya desplegando múltiples mecanismos. Cuando las células inmunes encuentran potenciales patógenos, se activan cascadas de s...
Read moreNuage Therapeutics (“Nuage”) announces today the successful closing of a €12 million Seed financing to support the development of its lead program and validate its pioneering drug discovery plat...
Read moreOryzon Genomics, S.A., presented yesterday positive preclinical efficacy data of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor
Read moreThe findings can inform national programmes on the use of antimalarials for treatment and chemoprevention, and the impact of future interventions
Read moreTagworks Pharmaceuticals BV (“Tagworks”), the pioneer of Click-to-Release chemistry designed to deliver more effective and safer systemic therapies, today announced a $65 million Series A financin...
Read moreOneChain Immunotherapeutics (OCI), a clinical stage biotech company focused on the development of CAR-T candidates for the treatment of oncological diseases, today announced the closing of a €6.7 mi...
Read more